AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) — Orlando, Florida

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) is a clinical research site located in Orlando, Florida, United States 32804.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Endometrial Cancer.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)?

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) conducted?

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) has 1 clinical trials on record, with 1 currently active. Their work covers Endometrial Cancer.

Is AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) accredited by Crixeo Health?

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.